Weight Loss Research Peptides
8 weight loss research peptides are grouped here so readers can compare related compounds without losing the source context behind each profile. This category currently includes Semaglutide, Tirzepatide, AOD-9604, Tesamorelin, 5-Amino-1MQ, Cagrilintide, Mazdutide, Retatrutide. Each profile links to a full research guide with mechanism notes, storage details, safety context, and citations where available.
The shared biology in this group centers on incretin signaling, appetite regulation, gastric emptying, glucose control, and energy balance. Some peptides in the category are supported by clinical literature, while others are limited to animal, in-vitro, or mechanistic research. That distinction matters. A peptide with human trial data should not be interpreted the same way as a compound with only early laboratory findings.
Researchers often use this category to compare outcomes related to body-weight change, glycemic control, appetite, satiety, and cardiometabolic markers. The most useful starting point is usually the peptide with the clearest citation trail, followed by related compounds that act through a different receptor or pathway. This makes it easier to compare study design, model choice, and endpoint selection across a group rather than reviewing one peptide in isolation.
Metabolic peptides require attention to nausea, glucose changes, hydration status, and dose-escalation design. For purchasing research materials, review the vendor guidance on the buy peptides page. For protocol-style education, compare this category with the stacking guide before choosing which profile to read next.
Peptides in This Category
Semaglutide
Semaglutide is a GLP-1 receptor agonist that mimics the effects of the naturally occurring hormone GLP-1. It has gained significant attention for its powerful effects on appetite regulation and blood sugar control, leading to substantial weight loss in research subjects.
Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist, representing a new class of medications for metabolic conditions. It has shown remarkable efficacy in weight loss and glycemic control studies, often surpassing the results of single-receptor agonists.
AOD-9604
AOD-9604 is a modified fragment of human growth hormone (HGH) specifically designed to have the fat-reducing effects of HGH without the negative side effects on blood sugar or growth. It corresponds to the C-terminal portion of HGH.
Tesamorelin
Tesamorelin is a synthetic form of growth hormone-releasing hormone (GHRH). It is FDA-approved for reducing excess abdominal fat in HIV patients with lipodystrophy. It has become of interest for its ability to reduce visceral adipose tissue.
5-Amino-1MQ
Let's clear something up right away: 5-Amino-1MQ isn't actually a peptide. It's a membrane-permeable small molecule that gets lumped into the peptide conversation because of how researchers and biohackers use it. Discovered by researchers at the University of Texas, it's a highly selective NNMT inhibitor that flips the metabolic switch in fat cells. Instead of acting like a crude central nervous system stimulant, it directly targets cellular energy machinery to shrink white adipose tissue.
Cagrilintide
Just when we thought GLP-1 agonists had peaked, researchers started looking at amylin. Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk specifically to run alongside semaglutide. The combination, dubbed CagriSema in clinical trials, produces weight loss numbers that straight-up rival bariatric surgery. It attacks appetite from a completely different neurological angle than tirzepatide or semaglutide, making it the ultimate plateau-breaker for subjects who have stalled on standard therapies.
Mazdutide
Developed originally by Eli Lilly and advanced by Innovent Biologics, Mazdutide (IBI362) functions as a dual GLP-1 and glucagon receptor agonist. Think of it as a synthetic, long-acting version of oxyntomodulin, a naturally occurring hormone that kills appetite while actively burning stored fat. The clinical data out of China right now is staggering, especially regarding its ability to aggressively clear out liver fat while matching or beating the weight loss seen with standard single-agonist drugs.
Retatrutide
Retatrutide is the heavyweight champ of the incretin world right now. Eli Lilly engineered this 39-amino-acid peptide to hit three different receptors at once: GLP-1, GIP, and Glucagon. While semaglutide targets one pathway and tirzepatide hits two, retatrutide's 'triple G' approach pushed clinical trial weight loss past the 24% mark in under a year. We haven't seen anything this potent before outside of bariatric surgery.